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Summary 
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We measured total and free plasma concentrations of ropivacaine following high-volume, 
high-dose local infiltration analgesia in nineteen patients aged 65 years or over undergoing 
unilateral total hip arthroplasty. The patients received 180 ml (360 mg) of ropivacaine which 
was injected into the deep and peri-capsular tissues, the gluteal muscles and fascia lata, and 
the subcutaneous tissues and skin. Patients were monitored for clinical symptoms and signs 
of systemic local anaesthetic toxicity. Total levels of plasma ropivacaine varied from 0.081 ± 
1.707 µg.ml-1 (mean 0.953 µg.ml-1). Free levels of plasma ropivacaine varied from 0.000 ± 
0.053 µg.ml-1 (mean 0.024 µg.ml-1). No samples reached the toxic threshold for venous 
ropivacaine concentration, although four patients exhibited mild symptoms consistent with 
local anaesthetic toxicity. One patient had episodes of complete heart block on ECG 
monitoring but plasma ropivacaine levels were below toxic levels. We conclude that plasma 
levels for ropivacaine associated with toxicity in a volunteer population (total 2.2 µg.ml-1, 
free 0.15 µg.ml-1) are not reached during local infiltration analgesia for hip arthroplasty in 
elderly patients. 
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Early mobilisation following total hip arthroplasty can facilitate patient recovery and 
minimise complications following surgery [1, 2]. Both central neuraxial blockade and 
peripheral nerve block can cause motor deficit and this has significant disadvantages for 
patients in terms of mobilisation. Therefore, alternative analgesic techniques have been 
developed to support both effective pain relief and patient recovery [3 - 5]. 
Local infiltration analgesia is an increasingly popular technique for the management 
of early postoperative pain although concerns have been expressed regarding the safety of 
injecting large volumes of local anaesthetic into hip or knee joints during orthopaedic 
procedures [6]. 
The aim of this descriptive observational study was to analyse the total and free 
plasma concentrations of ropivacaine following high-volume, high-dose local infiltration 
analgesia in patients undergoing total hip arthroplasty. In addition to plasma levels of 
ropivacaine, we also monitored patients for symptoms or signs of local anaesthetic toxicity. 
 
Methods 
The study protocol was approved by the regional ethics committee (November 2011; 
11/WS/0086) and was conducted in accordance with the Declaration of Helsinki. Twenty 
patients gave written and informed consent for inclusion in the study. We included patients 
\ having unilateral total hip arthroplasty. The exclusion criteria were sensitivity or 
allergy to amide anaesthetics, patients who were unable to give consent and those with 
cardiac, respiratory, hepatic or renal failure. If the planned operation or anaesthetic technique 
changed after consent had been obtained the patient was withdrawn from the study. 
All patients followed the standardised enhanced recovery programme of our 
institution. This comprises a package of care including pre-operative education, multimodal 
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analgesia and accelerated rehabilitation. The anaesthetic/analgesic technique consists of 
regional anaesthesia, pre- and post-operative analgesia and the use of local infiltration of 
ropivacaine during hip arthroplasty. 
All patients were admitted the day before surgery and received oral temazepam 20 mg 
and gabapentin 600 mg at night. On the day of surgery, patients received oral temazepam 20 
mg, paracetamol 1 g and dexamethasone 10 mg 2 h pre-operatively. A 16G intravenous 
cannula (Becton Dickinson, Swindon, UK) was sited pre-operatively and a baseline venous 
blood sample was taken. Heart rate and non-invasive blood pressure monitoring were 
instituted in the pre-operative reception area in addition to 24-h ECG monitoring (Seer Light 
Recorder, GE, Amersham, UK) to enable rhythm analysis. 
Spinal anaesthesia was performed at L3-4 using 2.5 ml hyperbaric bupivacaine 5 
mg.ml-1. All patients received propofol sedation using a target-controlled infusion pump and 
were monitored by pulse oximetry in addition to those already commenced. 
At the beginning of the surgical procedure, tranexamic acid 2.5 g was administered. 
Local anaesthetic infiltration was performed by the surgeon intraoperatively using 180 ml of 
plain ropivacaine 2 mg.ml-1.  Circumferential infiltration of the deep and peri-capsular tissues 
with up to 80 ml was followed by infiltration of the gluteal muscles and fascia lata with 
approximately 70 ml. Finally, 30 ml was used to infiltrate the subcutaneous tissues and skin 
to complete the total of 180 ml. Wound drains were not used. 
Venous blood samples were taken at 5, 10, 15, 20, 25, and 30 min, then 1, 4 and 24 h 
following injection of local anaesthetic. Patients were asked about the presence of symptoms 
of local anaesthetic toxicity (light-headedness, blurred vision, tingling of the tongue or 
visual/auditory disturbances). In addition, more significant signs such as loss of 
consciousness, seizures or cardiac arrest were recorded. Intermittent heart rate and blood 
pressure readings and continuous 24-h ECG monitoring with rhythm analysis were recorded 
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study occurred following the final blood sample at 24 h and removal of the ECG monitor. 
Blood samples were centrifuged immediately after sampling by the Biochemical 
laboratory at the study site before being transferred to the Institute of Pharmacy and 
Biomedical Sciences, University of Strathclyde, Glasgow. Samples were analysed by the 
buffering of blood samples before separation of free and bound ropivacaine using equilibrium 
dialysis [7]. When analysis could not proceed immediately, samples were frozen, stored at 
minus 20ºC and then subsequently thawed prior to testing. The measurement of standards and 
samples was performed using liquid chromatography-mass spectrometry on a Surveyor 
HPLC system combined with an Orbitrap mass spectrometer (Thermo Fisher Scientific, 
Hemel Hempstead, UK). The results were analysed with descriptive statistics using GraphPad 
Prism Mac V6.0b software (GraphPad Software, San Diego, California). The maximum 
tolerated venous concentrations of ropivacaine were set at 2.2 µg.ml-1  for total plasma 
ropivacaine concentration and 0.15 µg.ml-1 for free plasma ropivacaine concentration as 
previously published in a volunteer population [8]. 
 
Results 
The data collection took place from August 2012 to March 2013. Twenty patients 
gave consent for inclusion in the study. Following consent, one patient (H4) was found not to 
meet the inclusion criteria and was excluded. The remaining 19 patients all completed the 
study. The mean (SD) patient age was 76.0 (6.3) y, weight 72.5 (15.3) kg and body mass 
index 27.3 (4.2) kg.m-2. Two patients were ASA grade 1, 13 were grade 2 and four were 
grade 3. Patient characteristics and peak concentration (Cmax) data are presented in Table 1. 
A total of 184 blood samples were collected for analysis. Six samples were missed due to 
venesection difficulties. 
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Excluding baseline samples, total plasma ropivacaine levels varied from 0.081 ± 
1.707 µg.ml-1 with a mean of 0.953 µg.ml-1 (Fig. 1a). The free levels of ropivacaine varied 
from 0.000 ± 0.053 µg.ml-1 with a mean of 0.024 µg.ml-1 (Fig. 1b). The maximum doses were 
below the toxic thresholds of 2.2 µg.ml-1 for total and 0.15 µg.ml-1 for free plasma 
ropivacaine concentration established in a volunteer population [8]. 
Four patients exhibited mild symptoms consistent with local anaesthetic toxicity. 
These were transient dizziness, nausea and blurred vision and occurred at the times specified 
in Table 2. All symptoms resolved without treatment. 
One patient was found on ECG monitoring to have had episodes of complete heart 
block during the study period. Analysis showed that maximum plasma ropivacaine levels 
during these episodes were 1.12 µg.ml-1 (total) and 0.03 µg.ml-1 (free). Subsequent telemetry 
over the postoperative stay revealed further episodes of complete heart block and the patient 
underwent implantation of a permanent pacemaker. 
 
Discussion 
This study aimed to assess the plasma ropivacaine concentrations during local 
infiltration analgesia for hip arthroplasty. Our results demonstrated that neither the total nor 
free levels of plasma ropivacaine reached potentially toxic venous concentrations of 
ropivacaine.  
Following the description of the local infiltration analgesia technique for hip and knee 
arthroplasty [3], several papers were published which reported equivalent or improved 
outcomes when compared to other regional analgesic techniques [9, 10]. Conversely, there 
remains debate regarding whether local infiltration analgesia for hip arthroplasty provides 
additional pain relief within a multimodal analgesic regimen [11]. The effectiveness of local 
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infiltration analgesia in terms of pain scoring and postoperative functional recovery lies 
outside the scope of this study. 
Studies published for local infiltration analgesia have primarily concentrated on 
plasma ropivacaine concentrations after knee arthroplasty [12-14]. In addition, although there 
are studies on hip surgery patients that show ropivacaine levels below the accepted toxic 
limits [15], it has been recognised as a limitation that free (or unbound) levels were not 
analysed. To our knowledge only one previous study has reported the plasma concentrations 
following hip arthroplasty with the use of levobupivacaine, but data for free ropivacaine 
concentration levels are not available [16]. The free proportion of a drug is more likely to be 
predictive of toxicity than the total concentration, therefore we feel that this study provides 
evidence that local infiltration with ropivacaine can be used safely in elderly patients 
undergoing total hip arthroplasty. 
Study patients received a total volume of 180 ml 0.2% ropivacaine. The mean dose 
received was 5.2 mg.kg-1 with a range from 3.5-6.8 mg.kg-1. All patients received a dose 
JUHDWHUWKDQWKHPDQXIDFWXUHUV¶UHFRPPHQGHGPD[LPXPGRVHRIPJNJ-1. Recent studies 
have demonstrated symptomatic local anaesthetic toxicity following an injection of 
ropivacaine into the layers of the abdominal wall [17]. Our results give support to the 
hypothesis that local anaesthetic plasma levels may vary depending on the tissues into which 
the drug is administered [18] and that the periarticular hip region is a relatively safe 
anatomical compartment for large volumes of local anaesthetic. However, the optimal dose 
for local infiltration analgesia in hip arthroplasty is as yet unknown and should be subject to 
further studies. We used ropivacaine without any additives although there is discussion on the 
relative merits of administering ropivacaine with adjuvants such as adrenaline or ketorolac 
[19]. Plasma ropivacaine levels are unlikely to be higher with adrenaline-containing 
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solutions, although it should be noted that ropivacaine has intrinsic vasoconstrictor 
properties. 
The study was designed to detect potential signs of local anaesthetic toxicity. We 
found that five patients had symptoms or signs consistent with toxic plasma levels of 
ropivacaine. In these patients, the symptoms observed could have been attributable to factors 
other than ropivacaine toxicity such as the effects of sedation or the use of opioid analgesia. 
The free level of ropivacaine at the time of the onset of symptoms remained below the mean 
venous toxic level. The patient who showed complete heart block on the ECG monitor 
continued to display conduction defects on telemetry in the days following surgery. 
Subsequent investigation revealed that the patient had experienced dizziness in the preceding 
months often associated with emesis. Before discharge after surgery, the patient underwent 
implantation of a permanent pacemaker for complete heart block presumed secondary to 
cardiac sarcoidosis. 
This study has a number of limitations and implications. Firstly, the toxic reference 
levels used were provided from a study performed on healthy young volunteers. It is accepted 
that the toxic thresholds may be different in elderly patients although, to our knowledge, such 
toxicity data does not exist. Elderly patients may have reduced organ blood flow and function 
that can decrease the clearance of local anaesthetic drugs [20]. However, this is more relevant 
when considering repeated doses of local anaesthetic. In addition, although peak plasma 
concentrations and plasma protein binding are similar in elderly people and young adults 
[21], axonal function deteriorates and nerve morphology changes with advancing age [22]. 
This may result in toxic symptoms or signs at lower plasma levels than would be the case 
with young adults. 
It is possible that the injection technique might not deliver ropivacaine to the intended 
anatomical sites during the procedure. Injection into more vascular structures could 
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potentially have altered the pharmacokinetic profiles seen, leading to more rapid uptake into 
the plasma; however we did not observe this. 
Target-controlled propofol sedation was used for all study patients. Subtle symptoms 
or signs of local anaesthetic toxicity may have been masked in the immediate postoperative 
period due to sedation. Equally, the use of sedation may have been responsible for the 
transient dizziness, blurred vision and nausea observed. 
The use of ECG Holter monitoring provided heart rate analysis throughout the study 
period and allowed the detection of dysrhythmias that may have been caused by toxic local 
anaesthetic plasma levels. However, it may not have been sufficiently sensitive to detect the 
more subtle changes in ECG morphology that can be associated with local anaesthetic 
toxicity such as P-R prolongation or QRS widening. Other studies have used serial ECG 
measurements to determine whether cardiac electrophysiology is altered by local anaesthetics 
[8]. 
In conclusion, this study shows that plasma levels of ropivacaine associated with 
toxicity in a volunteer population are not reached during high-volume, high-dose local 
infiltration analgesia using 360 mg of ropivacaine for total hip arthroplasty in elderly 
patients. 
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Table 1. Patient characteristics and peak plasma ropivacaine concentration (Cmax) data in 19 cases of 
local infiltration analgesia. 
 
Patient Age 
(y) 
Height 
(m) 
Weight 
(kg) 
BMI 
(kg.m-2) 
Ropivacaine 
dose  
(mg.kg-1) 
Total  
(µg.ml-1) 
Free  
(µg.ml-1) 
H1 72.9 1.61 86 33.2 4.2 1.707 0.028 
H2 81.0 1.64 66 24.5 5.5 1.593 0.053 
H3 75.5 1.61 75 28.9 4.8 1.342 0.040 
H5 65.3 1.59 81 32.0 4.4 1.642 0.039 
H6 67.8 1.56 69 28.4 5.2 0.722 0.014 
H7 80.7 1.54 64 27.0 5.6 1.149 0.030 
H8 65.6 1.98 101 25.8 3.6 0.790 0.026 
H9 75.9 1.50 68 30.2 5.3 1.394 0.022 
H10 78.5 1.68 103 36.5 3.5 0.797 0.037 
H11 80.0 1.70 66 22.8 5.5 0.944 0.034 
H12 80.1 1.77 91 29.0 4.0 1.004 0.014 
H13 82.3 1.73 89 29.7 4.0 0.958 0.041 
H14 72.8 1.57 61 24.7 5.9 1.370 0.041 
H15 68.8 1.64 72 26.8 5.0 0.911 0.024 
H16 72.8 1.50 56 24.9 6.4 0.996 0.027 
H17 90.0 1.50 55 24.4 6.5 1.189 0.035 
H18 74.7 1.59 59 23.3 6.1 1.351 0.038 
H19 77.9 1.72 53 17.9 6.8 1.268 0.030 
H20 81.1 1.49 62 27.9 5.8 1.061 0.040 
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Table 2. Details of four patients exhibiting potential symptoms of systemic toxicity with concurrent 
total and free plasma ropivacaine concentrations. 
 
Patient Symptom Time reported Plasma Levels (µg.ml-1) 
   Total Free 
H5 Dizziness 25 min 1.474 0.036 
H7 Nausea 30 min 1.149 0.028 
H7 Blurred vision 4 h 0.943 0.012 
H15 Dizziness 4 h 0.851 0.019 
H6 Blurred vision 24 h 0.722 0.008 
 
 
 
 
 
 
  
 16 
Caption to figure 1 
 
Figure 1. Plasma ropivacaine concentrations following local infiltration analgesia (a) total (b) free. 
Values are mean (line), SD (error bars). 
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